Somatostatin Receptor Expression in Adrenocortical Carcinoma

#1641

Introduction: Adrenocortical carcinoma (ACC) is an uncommon neoplasm with an estimated annual incidence of 0.5-2 cases per million population. Surgery of the adrenal tumor is the major treatment. When complete tumor removal is not possible, or in case of recurrence, medical treatment with O,p’DDD(mitotane) is recommended. The treatment of ACC is currently based on the mitotane partial responses have been described in 19-34% of cases, and there are single reports of complete responses.The discovery of somatostatin (SST) and the identification of stable SST analogs with a longer half-life have raised new hopes for the treatment of endocrine tumors.

Aim(s): The explore somatostatin receptor protein expression in ACC.

Materials and methods: Tumoral adrenal tissues were obtained surgically from 10 patients with ACC (2 men, 8 women; age 44±9). Malignancy was diagnosed according to the histopathological criteria proposed by Weiss. Immunohistochemistry (IHC) was performed with Anti-somatostatin receptor 2 and 5 antibodies. The expression of SSTR 2 and 5 was considered positive if the membrane staining had been presented.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Voronkova I, Gurevich L, Kazanceva I, Krivosheev A, Britvin T,

Keywords: Adrenocortical carcinoma, Somatostatin receptor, Immunohistochemistry,